We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sensitive Blood Test Detects Prion Diseases

By LabMedica International staff writers
Posted on 11 Jul 2011
A novel assay has been developed that will rapidly screen blood plasma for variant Creutzfeldt-Jacob disease (vCJD). More...


An integrated antibody-based approach with an improved real-time quaking-induced protein conversion (RT-QuIC) reaction enhanced the detection of vCJD brain tissue diluted into human plasma.

Scientists at the US National Institute of Allergy and Infectious Diseases, (NIAID; Bethesda, MD, USA), collaborated with scientists from Prionics AG, (Schlieren-Zurich, Switzerland), to develop the sensitive bioassay. RT-QuIC, developed only recently, detects the abnormal form of prion protein, which, in purified form, resembles amyloid fibrils. This combined assay, which they call enhanced QuIC (eQuIC), detects approximately 2 attograms (10-18 grams) per mL of proteinase K–resistant prion protein, a 1014-fold dilution, indicating a 10,000-fold increase in sensitivity compared with previously reported methods of vCJD brain tissue detection.

In addition, in early preclinical studies, the eQuIC screening tool has been found to distinguish between plasma and serum samples from scrapie-infected and uninfected hamsters. This rapid and sensitive screening tool that detects prion diseases, also known as transmissible spongiform encephalopathies, would aid in the prevention of prion disease transmission within and between species because animals and people are commonly infected for years before symptoms of the disease appear.

Byron Caughey, PhD, senior investigator in the NIAID Laboratory of Persistent Viral Diseases, said, ""The eQuIC assay in particular provides a practical, high-throughput, and rapid means of testing for amounts of partially protease-resistant form of the host's prion protein that are several orders of magnitude below those typically required to cause prion disease by intracerebral inoculation into animals."

The authors concluded that the remarkable resistance to inactivation of prions relative to other pathogens also makes it important to develop practical assays for prion contamination in a wide variety of materials, such as foods, feeds, transplanted tissues, medical devices, agricultural wastes and by-products, soils, water sources, and other environmental samples. The article was published on May 10, 2011 in the journal mBIO.

Related Links:
US National Institute of Allergy and Infectious Diseases
Prionics AG


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.